Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-03-06 3:14 pm Purchase | 2025-02-10 | 13G | Odysight.ai Inc. ODYS | Moshe Arkin | 7,926,329 41.900% | 7,926,329 (New Position) | Filing History |
| 2024-08-26 10:01 am Purchase | 2024-08-19 | 13G | Eiger BioPharmaceuticals, Inc. EIGR | Moshe Arkin | 149,371 10.090% | 96,300 (+181.46%) | Filing History |
| 2024-07-01 06:47 am Sale | 2024-06-21 | 13D | Eiger BioPharmaceuticals, Inc. EIGR | Moshe Arkin | 53,071 3.580% | -96,300 (-64.47%) | Filing History |
| 2024-04-08 09:28 am Purchase | 2024-04-19 | 13D | Sol-Gel Technologies Ltd. SLGL | Moshe Arkin | 18,154,564 60.800% | 4,000,000 (+28.26%) | Filing History |
| 2024-02-22 09:23 am Unchanged | 2023-07-28 | 13D | UroGen Pharma Ltd. URGN | Moshe Arkin | 1,369,315 4.440% | 0 (Unchanged) | Filing History |
| 2023-12-04 06:01 am Sale | 2023-11-14 | 13D | Eiger BioPharmaceuticals, Inc. EIGR | Moshe Arkin | 149,371 10.090% | -33 (-0.02%) | Filing History |
| 2023-11-24 06:01 am Unchanged | 2023-11-14 | 13D | Eiger BioPharmaceuticals, Inc. EIGR | Moshe Arkin | 149,404 10.090% | 0 (Unchanged) | Filing History |
| 2023-04-18 09:59 am Purchase | 2023-04-10 | 13G | Eiger BioPharmaceuticals, Inc. EIGR | Moshe Arkin | 149,404 10.150% | 58,971 (+65.21%) | Filing History |
| 2023-03-20 4:45 pm Sale | 2023-01-27 | 13D | Sol-Gel Technologies Ltd. SLGL | Moshe Arkin | 14,154,564 55.080% | -363,702 (-2.51%) | Filing History |
| 2023-02-02 2:25 pm Purchase | 2022-12-31 | 13G | Eiger BioPharmaceuticals, Inc. EIGR | Moshe Arkin | 90,433 6.160% | 29,559 (+48.56%) | Filing History |
| 2023-02-02 2:23 pm Sale | 2023-01-26 | 13G | Keros Therapeutics, Inc. KROS | Moshe Arkin | 1,371,074 4.980% | -441,241 (-24.35%) | Filing History |
| 2023-02-02 2:15 pm Purchase | 2022-12-31 | 13G | Oncorus, Inc. ONCR | Moshe Arkin | 2,508,481 9.660% | 1,041,392 (+70.98%) | Filing History |
| 2022-04-12 06:18 am Unchanged | 2022-04-11 | 13G | Keros Therapeutics, Inc. KROS | Moshe Arkin | 1,812,315 7.550% | 0 (Unchanged) | Filing History |
| 2022-04-11 4:57 pm Sale | 2022-04-11 | 13G | Keros Therapeutics, Inc. KROS | Moshe Arkin | 1,812,315 7.550% | -223,825 (-10.99%) | Filing History |
| 2022-03-08 08:58 am Purchase | 2022-03-01 | 13G | Eiger BioPharmaceuticals, Inc. EIGR | Moshe Arkin | 60,874 5.380% | 60,874 (New Position) | Filing History |
| 2021-12-02 4:15 pm Purchase | 2021-11-22 | 13G | Oncorus, Inc. ONCR | Moshe Arkin | 1,467,089 5.680% | 1,467,089 (New Position) | Filing History |
| 2021-05-10 11:21 am Purchase | 2021-04-29 | 13D | Werewolf Therapeutics, Inc. HOWL | Moshe Arkin | 2,046,634 7.400% | 2,046,634 (New Position) | Filing History |
| 2020-12-17 06:48 am Unchanged | 2020-12-17 | 13D | Keros Therapeutics, Inc. KROS | Moshe Arkin | 2,036,140 8.790% | 0 (Unchanged) | Filing History |
| 2020-11-25 06:31 am Unchanged | 2020-11-17 | 13D | Keros Therapeutics, Inc. KROS | Moshe Arkin | 2,036,140 8.790% | 0 (Unchanged) | Filing History |
| 2020-04-20 1:19 pm Purchase | 2020-02-13 | 13D | Sol-Gel Technologies Ltd. SLGL | Moshe Arkin | 14,518,266 62.210% | 818,330 (+5.97%) | Filing History |